BioCentury
ARTICLE | Company News

Ligand, Merck deal

October 20, 2014 7:00 AM UTC

Ligand received a $550,000 milestone payment under a 2011 deal granting Merck a worldwide license to Ligand's Captisol modified beta-cyclodextrin reformulation technology for use with the pharma's IV ...